Key facts
- This page summarizes Gail Cawkwell's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Jul 2022, 17:01.
Gail Cawkwell - 01 Jul 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ACRS
- Reported as of
- 01 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2022, 17:01:25 UTC
- Prior SEC filing
- 05 Jul 2022
- Next SEC filing
- 03 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gail Cawkwell filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 05 Jul 2022.
Change
- Previous filing in this sequence was filed on 05 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRS
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +210,000
- Change %
- Price
- $0.000000
- Shares after
- 210,000
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 210,000
- Exercise price
- $13.83
- Footnotes
- F1
ACRS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
Footnote F3
The shares underlying these restricted stock units vest in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.